Navigation Links
Next steps for Tenofovir gel: CONRAD and TIA sign license agreement
Date:6/14/2011

Arlington, VA, USA and Pretoria, South Africa -- CONRAD and the South African Government's Technology Innovation Agency (TIA) today announced a license agreement that grants TIA the rights to manufacture and distribute Tenofovir1% gel in Africa. TIA will in turn set up a joint venture for the manufacturing and distribution of the gel in South Africa and other licensed territory, which includes the African continent. The gel will be registered, manufactured and distributed by ProPreven, a joint venture involving TIA, Cipla Medpro and iThemba Pharmaceuticals.

Dr. Henry Gabelnick, Executive Director of CONRAD stated, "Although confirmatory results are necessary to secure regulatory approval, this license agreement creates a process to move approval and access forward. It's important to prepare for success in order to get this prevention tool to women who need it the most, as soon as possible."

Women who used Tenofovir 1% gel in a South African study called CAPRISA 004 had 39% fewer HIV infections and 51% fewer genital herpes infections compared to women who used a placebo gel. These results provided the first evidence that an antiretroviral drug delivered in a gel form can reduce sexually transmitted infections of HIV and herpes in women. Gilead Sciences licensed the drug royalty-free to CONRAD, who manufactured and supplied the gel for the trial.

"TIA has agreed to help facilitate the manufacture of this product so that it will be affordable and accessible to women, not only in South Africa, but the entire continent of Africa. While we have an enormous amount of work to accomplish before the product is available, we are creating a

mechanism to expedite the process to the market," said Pontsho Maruping, Group Executive: Sectors at TIA. "We hope this can be accomplished in the next three years," Ms. Maruping added.

CONRAD is spearheading regulatory work toward registration in the U.S., South Africa and Europe. The FDA has granted Fast Track approval designation for Tenofovir1% gel, which facilitates the development and expedites the review of drugs that are intended for treating serious diseases and fill an unmet medical need. CONRAD's clinical team is currently working on expanded studies that will compare various dosing regimens and clinical trials requested by the FDA, including safety in adolescents and drug-drug interaction studies.


'/>"/>

Contact: Annette Larkin
alarkin@conrad.org
703-772-6427
CONRAD
Source:Eurekalert

Related medicine news :

1. New Lumension Webcast Highlights Key Steps to Prepare Healthcare Firms and Business Associates to Comply with New HITECH Act
2. UAB-led study shows simple steps could reduce stillbirths by up to 1 million
3. KID HEALTHY-Steps to Healthy Living Kicks Off 2010 Campaign to Make Southern California Kids and Families Healthier
4. New York Medical Malpractice Attorney Recommends Cancer Patients Take Precautionary Steps Before Undergoing Radiation Therapy
5. Consumers over age 50 should consider steps to cut copper and iron intake
6. B. Eliot Cole, MD, Steps Down as Executive VP at Aventine Healthsciences and Executive Director of American Society of Pain Educators
7. Strep steps up in urinary tract infections
8. Attain Fertility Offers 3 Steps to Protect Emotional Well-being While Trying to Get Pregnant
9. More Steps a Day Lead to Better Health
10. Khannna Institute to offer Crystalens in Quarter Diopter Steps
11. Five Essential Steps to Choosing Toning Footwear
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... ... named Agency of Record (AOR) for Theravent, Inc. , the makers of ... parent company, Foundation Consumer Healthcare, is now working to expand distribution in anticipation ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Alive for ... who wish to overcome their mental health struggles. The Alive team uses advanced ... says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... is seeking candidates to serve on its Accreditation and Standards Committees to ... ultimate mission is improving image quality and reducing patient radiation dose,” reports ...
(Date:4/21/2017)... ... ... and Overseer at The House of Yahweh in Abilene, Texas, wrote an open letter this ... to peace plan. Yisrayl says war has never brought peace and he knows the only ... , Yisrayl says war drums are beating all over the media and the tensions ...
(Date:4/21/2017)... ... April 21, 2017 , ... A ... for older shoulder replacement patients; post-operative recovery just might be even better than ... patients presenting with osteoarthritis following surgery: 262 patients under 65 and 103 patients ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  IRIDEX Corporation (Nasdaq: IRIX ) ... the first quarter 2017 after the close of trading ... will host a corresponding conference call beginning at 2:30 ... interested in listening to the conference call may do ... (703) 326-3030 for international callers, using conference ID: 92158987.  ...
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
Breaking Medicine Technology: